Salvage chemotherapy for lymphoma with VP‐16, ifosfamide, and cisplatin

Craig R. Nichols, Patrick J. Loehrer, Anne Greist, Paul S. Kubilis, Ronald Hoffman

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Between 1983 and 1985, we conducted a phase II clinical trial using VP‐16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma. Twenty‐eight patients with bidimensional measurable disease were treated with VP‐16 (75 mg/m2), ifosfamide (1.2 g/m2), and cisplatin (20 mg/m2) as daily intravenous infusions for 5 consecutive days. N‐Acetyl‐cystein, 2 g orally every 6 h, was given as a uroepithelial protective agent. All patients had received extensive combination chemotherapy prior to beginning VIP (median number of regimens = 2). Of the 25 patients evaluable for response, 2 patients achieved complete remission and 7 achieved partial remission for an overall objective response rate of 36%. The length of responses ranged from 2 months to 13 months. The predominant toxicity of VIP was myelosuppression. Of 23 patients receiving more than one course of VIP, 17 (73%) had dose reductions or delays related to poor hematologic tolerance of therapy. Uroepithelial and renal toxicity were mild. VIP demonstrates therapeutic activity in refractory lymphoma and appears comparable to other ifosfamide/VP‐16 based salvage regimens.

Original languageEnglish
Pages (from-to)12-16
Number of pages5
JournalMedical and Pediatric Oncology
Issue number1
StatePublished - 1988
Externally publishedYes


  • antitumor activity
  • combination chemotherapy
  • hematologic tolerance
  • myelosuppression
  • refractory lymphoma
  • toxicity


Dive into the research topics of 'Salvage chemotherapy for lymphoma with VP‐16, ifosfamide, and cisplatin'. Together they form a unique fingerprint.

Cite this